ORGO

After three straight years of shrinking revenue (2021 $467M → 2023 $433M), Organogenesis has re-accelerated hard: FY2025 revenue of $564M is up 17% and marks a fresh high, with a 64.9% gross margin and operating income swinging to $44.7M (7.9% margin) from almost nothing. Net income of $37.0M and 12.3% ROE off a lightly-levered balance sheet (liabilities/equity 0.55x, $300M equity, $93.7M cash) make the headline P/E of 15.7 and P/S of 0.5 look inexpensive for a profitable, growing biologics business. On the surface this is a cheap recovery story.

The problem is earnings quality. Despite $37M of reported net income, operating cash flow was NEGATIVE $10.3M — a 172% swing to the wrong side — and with $14.2M of capex, free cash flow is deeply negative. Cash fell 30.9% to $93.7M while total liabilities jumped 46.4% and current liabilities rose 29.2%. Profit that doesn't convert to cash, in a business whose products are reimbursed by unstable government payers, is exactly the combination that warrants caution. The company also still carries a negative retained-earnings balance (accumulated deficit of $3.08M) and only recently remediated previously-reported material weaknesses — which management explicitly warns could recur.